Vera Therapeutics plans to raise approximately $261 million through a public offering of 6,138,108 shares of Class A common stock at $42.50 per share, with underwriters led by J.P. Morgan and Goldman Sachs.

The BK virus infection market is experiencing growth due to increasing organ transplant procedures, lack of FDA-approved drugs, and rising awareness. Innovative therapies and personalized medicine approaches are emerging to address treatment challenges.

Vera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.

Vera Therapeutics reported a wider net loss of $76.5 million in Q2 2025, with significant progress on its lead drug atacicept for treating Immunoglobulin A Nephropathy (IgAN). The company showed positive clinical trial results and plans to submit a Biologics License Application to the FDA in Q4 2025.

Vera Therapeutics granted stock options and restricted stock units to 15 new employees, with options to purchase 133,500 shares and RSUs for 73,695 shares, vesting over four years.

Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.

Vera Therapeutics, a late-stage biotechnology company, announced the grant of stock options and restricted stock units to 17 new employees as an inducement to their employment. The grants are part of the company's Inducement Plan and are subject to vesting conditions.

Vera Therapeutics, a late-stage biotechnology company, announced plans to raise $300 million through a public offering of its Class A common stock. The company is developing treatments for serious immunological diseases, including IgAN and lupus nephritis.

Vera Therapeutics announced positive long-term results from its Phase 2b study of atacicept in immunoglobulin A nephropathy (IgAN), showing stabilized kidney function through 96 weeks. The data supports atacicept's potential to modify the disease and prevent kidney failure in IgAN patients.

Vera Therapeutics announced that it granted inducement awards, including stock options and restricted stock units, to its new Chief Operating Officer and ten new employees. The awards are intended to incentivize and retain the new hires.

BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches.

BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares of Class A common stock to five new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).